–Attack progression halted in median 19.8 minutes after treatment with sebetralstat in both KONFIDENT and KONFIDENT-S trials– –Sebetralstat data demonstrated rapid relief and resolution of severe HAE ...

Optimal care for female and pediatric patients with hereditary angioedema (HAE) requires consideration of several population-specific issues. For women, these include menstruation, contraception, ...

While all cases of hereditary angioedema (HAE) should be managed by HAE specialists, optimal management requires a multidisciplinary team of collaborating physicians and other personnel, including ...

KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing that oral EKTERLY (sebetralstat) provided rapid, well-tolerated on-demand treatment for 172 hereditary ...

Hereditary angioedema (HAE) is a disease that, due to its rare nature, can pose difficulties for both patients and medical professionals. A new survey of allergists/immunologists from the American ...

"Hereditary Angioedema Drugs Market"Hereditary Angioedema Companies are Ionis Pharmaceuticals, Astria Therapeutics, KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL ...

Pharvaris, a biopharmaceutical company focusing on innovative oral treatments for bradykinin-mediated diseases like hereditary angioedema (HAE), recently shared data from the European Academy of ...

Hereditary angioedema (HAE) is a serious, potentially fatal disease of recurrent swelling of various subcutaneous and submucosal tissues throughout the body. Swelling is mediated by uncontrolled ...

Hereditary angioedema (HAE) is a genetic syndrome caused by a functional deficit in complement C1 inhibitor that results in recurrent episodes of nonpruritic swelling of the hands, feet, arms, legs, ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Angiotensin-converting enzyme inhibitors (ACEi) are the leading cause of drug-induced angioedema in the USA, with an incidence of 0.1–0.7%. While ACEi-induced angioedema (ACEi-AE) typically affects ...